company background image
6785 logo

Alar Pharmaceuticals TPEX:6785 Stock Report

Last Price

NT$151.50

Market Cap

NT$10.1b

7D

4.1%

1Y

-24.4%

Updated

21 Nov, 2024

Data

Company Financials +

Alar Pharmaceuticals Inc.

TPEX:6785 Stock Report

Market Cap: NT$10.1b

6785 Stock Overview

A drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. More details

6785 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends2/6

Alar Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alar Pharmaceuticals
Historical stock prices
Current Share PriceNT$151.50
52 Week HighNT$465.00
52 Week LowNT$143.00
Beta0.11
11 Month Change-9.55%
3 Month Change-26.63%
1 Year Change-24.44%
33 Year Change203.91%
5 Year Changen/a
Change since IPO236.67%

Recent News & Updates

Recent updates

We're Hopeful That Alar Pharmaceuticals (GTSM:6785) Will Use Its Cash Wisely

Jan 13
We're Hopeful That Alar Pharmaceuticals (GTSM:6785) Will Use Its Cash Wisely

Shareholder Returns

6785TW PharmaceuticalsTW Market
7D4.1%0.6%-0.8%
1Y-24.4%9.2%29.0%

Return vs Industry: 6785 underperformed the TW Pharmaceuticals industry which returned 9.2% over the past year.

Return vs Market: 6785 underperformed the TW Market which returned 29% over the past year.

Price Volatility

Is 6785's price volatile compared to industry and market?
6785 volatility
6785 Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement3.8%
Market Average Movement4.5%
10% most volatile stocks in TW Market8.0%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6785's share price has been volatile over the past 3 months compared to the TW market.

Volatility Over Time: 6785's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
201622Yung-Shun Wenwww.alarpharm.com

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson’s disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

Alar Pharmaceuticals Inc. Fundamentals Summary

How do Alar Pharmaceuticals's earnings and revenue compare to its market cap?
6785 fundamental statistics
Market capNT$10.12b
Earnings (TTM)NT$400.72m
Revenue (TTM)NT$474.29m

25.3x

P/E Ratio

21.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6785 income statement (TTM)
RevenueNT$474.29m
Cost of RevenueNT$2.03m
Gross ProfitNT$472.26m
Other ExpensesNT$71.54m
EarningsNT$400.72m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)6.00
Gross Margin99.57%
Net Profit Margin84.49%
Debt/Equity Ratio0%

How did 6785 perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

22%

Payout Ratio